Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients. / Becskei, Csilla; Willesen, Jakob L.; Schnyder, Manuela; Wozniakiewicz, Magda; Miroshnikova, Nataliya; Mahabir, Sean P.
I: Parasites and Vectors, Bind 13, Nr. 1, 385, 2020.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Field safety and efficacy of an orally administered combination of sarolaner, moxidectin and pyrantel (Simparica Trio®) for the prevention of angiostrongylosis in dogs presented as veterinary patients
AU - Becskei, Csilla
AU - Willesen, Jakob L.
AU - Schnyder, Manuela
AU - Wozniakiewicz, Magda
AU - Miroshnikova, Nataliya
AU - Mahabir, Sean P.
PY - 2020
Y1 - 2020
N2 - Background: Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) for the prevention of A. vasorum infection in dogs (prevention study). A survey study was conducted concurrently to determine the infection pressure in the same areas. Methods: Prevention and survey studies were both conducted at the same veterinary clinics in endemic hot spots for A. vasorum in Denmark and Italy. The prevention study was a randomized, placebo controlled, double masked study where 622 client-owned dogs were treated and tested at 30 days intervals for 10 months. In the survey study 1628 dogs that were at risk of infection and/or were suspected to be infected were tested by fecal and/or serological methods, and the percent of dogs positive for A. vasorum was calculated. Results: In the prevention study, there were no adverse events related to treatment with Simparica Trio ® . Two placebo-treated animals became infected with A. vasorum during the 10-month study period, while none of the dogs in the combination product-treated group became infected. In the survey study, 12.2% of the study dogs were found positive to A. vasorum, indicating high exposure to the parasite during the period of the prevention study. Conclusions: Monthly oral treatment with the combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) was 100% effective in the prevention of natural infection with A. vasorum in dogs in highly endemic areas. In endemic areas, A. vasorum occurrence in dogs at risk is considerable.[Figure not available: see fulltext.]
AB - Background: Infection with the cardiopulmonary nematode Angiostrongylus vasorum may cause severe disease in dogs, therefore prophylactic treatments are necessary to prevent infection in dogs at risk. A clinical field study was conducted to demonstrate the efficacy and safety of an oral combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) for the prevention of A. vasorum infection in dogs (prevention study). A survey study was conducted concurrently to determine the infection pressure in the same areas. Methods: Prevention and survey studies were both conducted at the same veterinary clinics in endemic hot spots for A. vasorum in Denmark and Italy. The prevention study was a randomized, placebo controlled, double masked study where 622 client-owned dogs were treated and tested at 30 days intervals for 10 months. In the survey study 1628 dogs that were at risk of infection and/or were suspected to be infected were tested by fecal and/or serological methods, and the percent of dogs positive for A. vasorum was calculated. Results: In the prevention study, there were no adverse events related to treatment with Simparica Trio ® . Two placebo-treated animals became infected with A. vasorum during the 10-month study period, while none of the dogs in the combination product-treated group became infected. In the survey study, 12.2% of the study dogs were found positive to A. vasorum, indicating high exposure to the parasite during the period of the prevention study. Conclusions: Monthly oral treatment with the combination of sarolaner, moxidectin and pyrantel (Simparica Trio ® ) was 100% effective in the prevention of natural infection with A. vasorum in dogs in highly endemic areas. In endemic areas, A. vasorum occurrence in dogs at risk is considerable.[Figure not available: see fulltext.]
KW - Angiostrongylus vasorum
KW - French heartworm
KW - lungworm
KW - prevention
KW - Simparica Trio
KW - survey
U2 - 10.1186/s13071-020-04262-4
DO - 10.1186/s13071-020-04262-4
M3 - Journal article
C2 - 32727548
AN - SCOPUS:85088850810
VL - 13
JO - Parasites & Vectors
JF - Parasites & Vectors
SN - 1756-3305
IS - 1
M1 - 385
ER -
ID: 247501452